Apollon Formularies (AQSE:APOL) Net Change in Cash : £0.05 Mil (TTM As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Apollon Formularies's Net Change in Cash for the six months ended in Jun. 2023 was £0.05 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 was £0.05 Mil.

Apollon Formularies Net Change in Cash Historical Data

The historical data trend for Apollon Formularies's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Net Change in Cash Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

Net Change in Cash

Get a 7-Day Free Trial

0.20

-0.34

0.03

0.30

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
Net Change in Cash	Get a 7-Day Free Trial											0.06	1.25	-0.95	-0.30	0.05

Apollon Formularies Net Change in Cash Calculation

Apollon Formularies's Net Change in Cash for the fiscal year that ended in Dec. 2021 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-3.106	+	1.146	+	2.262	+	0
	=	0.30

Apollon Formularies's Net Change in Cash for the quarter that ended in Jun. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -0.031 + 0.089 + -0.008 + 0

= 0.05

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollon Formularies Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Apollon Formularies's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Net Change in Cash

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

Value Idea Contest Results Announcement; Win $1000 If Your Pick Doubles in 12 Months
By GuruFocus GuruFocus • 06-04-2013

Yacktman Funds Comments on Apollo Group
By Holly LaFon Holly LaFon • 03-13-2013

Jeff Auxier Interview with GuruFocus
By Holly LaFon Holly LaFon • 08-28-2012

FPA Capital Fund Finds Only 2 Stocks Matching Their Criteria in Q1
By Holly LaFon Holly LaFon • 04-10-2013

Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC
By Jimmy Xiao gurujx • 05-17-2015

5 Stocks to Avoid - January 2017
By Benjamin Clark Benjamin Clark • 01-14-2017

FPA Capital Fund Q1 2013 Commentary
By Holly LaFon Holly LaFon • 04-24-2013

Valuing Donald Yacktman's Portfolio: The Peter Lynch Fair Value
By Holly LaFon Holly LaFon • 07-02-2012

Richard Pzena Reduces APOL as Phoenix Rises for Others
By Sally Jones Sally Jones • 03-11-2013

5 Stocks Trading Near Their Historical Low P/S Ratios
By Holly LaFon Holly LaFon • 04-11-2012